Gary M. Onik, M.D., from the Center for Safer Prostate Cancer Therapy in Orlando, Fla., treated 120 patients' prostate tumors with cryoablation under ultrasound guidance, of whom 72 were at medium to high risk of recurrence. After a mean follow-up of 3.6 years, 93 percent of patients had stable levels of prostate-specific antigen with no evidence of cancer, even in the higher risk patients. There were no local recurrences in the treated areas, potency was maintained in 85 percent of the patients who were potent before the procedure, and all patients without previous prostate surgery remained continent. Kelvin Hong, M.D., and colleagues from Johns Hopkins University in Baltimore, evaluated computed tomography-guided, percutaneous cryoablation procedures in 73 renal masses (Bosniak III-IV lesions). The researchers found that efficacy and two-year survival were near 100 percent for disease stage T1aN0M0. A second study by the same group of researchers evaluated safety. "CT-guided percutaneous cryoablation for solid renal masses has an excellent safety profile with a CTCAE>1 complication rate of 7.4 percent," Hong and colleagues conclude. "There were no treatment-related deaths."
Tuesday, March 10, 2009
SIR: Cryoablation Safe and Effective for Prostate, Kidney
Procedure effective for localized tumors
10 mar 2009-- Minimally invasive cryoablation of localized prostate cancer and small localized kidney tumors is safe and effective, according to two studies presented at the Society of Interventional Radiology's annual meeting held Mar. 7 to 12 in San Diego.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment